|
 |
|
|||||||
|
|||||||||
Diabetes Care 30:1448-1453, 2007
DOI: 10.2337/dc06-2499
© 2007 by the American Diabetes Association
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epidemiology/Health Services/Psychosocial Research |
How Doctors Choose Medications to Treat Type 2 Diabetes
A national survey of specialists and academic generalists
1 General Medicine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
2 Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
3 Partners Telemedicine Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
4 Laboratory of Computer Science, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
5 Institute for Health Policy, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Address correspondence and reprint requests to Richard W. Grant, MD, MPH, 50-9 Staniford St., Boston, MA 02114. E-mail: rgrant{at}partners.org
OBJECTIVE—Glycemic control remains suboptimal despite the wide range of available medications. More effective medication prescription might result in better control. However, the process by which physicians choose glucose-lowering medicines is poorly understood. We sought to study the means by which physicians choose medications for type 2 diabetic patients.
RESEARCH DESIGN AND METHODS—We surveyed 886 physician members of either the Society of General Internal Medicine (academic generalists, response rate 30%) or the American Diabetes Association (specialists, response rate 23%) currently managing patients with type 2 diabetes. Respondents weighed the importance of 15 patient, physician, and nonclinical factors when deciding which medications to prescribe for type 2 diabetic subjects at each of three management stages (initiation, use of second-line oral agents, and insulin).
RESULTS—Respondents reported using a median of five major considerations (interquartile range 4–6) at each stage. Frequently cited major considerations included overall assessment of the patient's health/comorbidity, A1C level, and patient's adherence behavior but not expert guidelines/hospital algorithms or patient age. For insulin initiation, academic generalists placed greater emphasis on patient adherence (76 vs. 60% of specialists, P < 0.001). These generalists also identified patient fear of injections (68%) and patient desire to prolong noninsulin therapy (68%) as major insulin barriers. Overall, qualitative factors (e.g., adherence, motivation, overall health assessment) were somewhat more highly considered than quantitative factors (e.g., A1C, age, weight) with mean aggregate scores of 7.3 vs. 6.9 on a scale of 0–10, P < 0.001.
CONCLUSIONS—The physicians in our survey considered a wide range of qualitative and quantitative factors when making medication choices for hyperglycemia management. The apparent complexity of the medication choice process contrasts with current evidence-based treatment guidelines.
Abbreviations: ADA, American Diabetes Association • SGIM, Society of General Internal Medicine
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, et al. Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice Diabetes, August 1, 2008; 57(8): 2211 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Qualitative Factors Prove Important in Prescription Decisions DOC News, August 1, 2007; 4(8): 10 - 10. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |